Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences announces 1000th implant of NeuraGen™ Nerve Guide for Peripheral Nerve Repair
Integra LifeSciences announces 1000th implant of NeuraGenÔ Nerve Guide for Peripheral Nerve Repair Plainsboro, NJ / April 29, 2003 / -- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today reported that more than 1,000 NeuraGenÔ Nerve Guides have been implanted in patients in the United
View HTML
Toggle Summary Positive Results Of DuraGen® Dural Graft Matrix Clinical Experience Involving 169 Patients Presented At AANS 2003 Annual Meeting In San Diego
Positive Results Of DuraGen® Dural Graft Matrix Clinical Experience Involving 169 Patients Presented At AANS 2003 Annual Meeting In San Diego Plainsboro, New Jersey, April 29, 2003-- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that Dr. Peter D.
View HTML
Toggle Summary Investigators Present Results of Brain Tissue Oxygen Monitoring Clinical Experience at AANS 2003 Annual Meeting In San Diego
Investigators Present Results of Brain Tissue Oxygen Monitoring Clinical Experience at AANS 2003 Annual Meeting In San Diego Plainsboro, New Jersey, April 29, 2003-- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that members of the Department of Neurosurgery and Surgery
View HTML
Toggle Summary Integra LifeSciences Reports Record Pre-Tax Earnings and Revenues for the First Quarter 2003
Integra LifeSciences Reports Record Pre-Tax Earnings and Revenues for the First Quarter 2003 Cash Flows from Operations Totaled $8.8 Million PLAINSBORO, N.J., April 25, 2003 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (NasdaqNM: IART - News) today reported net income of $5.4 million,
View HTML
Toggle Summary Integra LifeSciences Holdings Corporation to Sell Additional $20 Million of Contingent Convertible Subordinated Notes
Integra LifeSciences Holdings Corporation to Sell Additional $20 Million of Contingent Convertible Subordinated Notes Plainsboro, New Jersey - April 11, 2003 - Integra LifeSciences Holdings Corporation (Nasdaq: IART) announced that the initial purchasers of its 2.5% Contingent Convertible
View HTML
Toggle Summary Integra LifeSciences Schedules Conference Call for Friday, April 25 to Discuss First Quarter 2003 Financial Results and Update Forward-Looking Financial Guidance
Integra LifeSciences Schedules Conference Call for Friday, April 25 to Discuss First Quarter 2003 Financial Results and Update Forward-Looking Financial Guidance PLAINSBORO, N.J.-April 9, 2003-- Integra LifeSciences Holdings Corporation (NASDAQ: IART - news) announced that it has scheduled a
View HTML
Toggle Summary Integra LifeSciences Confirms Earnings Guidance
Integra LifeSciences Confirms Earnings Guidance Plainsboro, NJ / March 26, 2003 / -- Integra LifeSciences Holdings Corporation (NASDAQ: IART - news) announced today that the Company's guidance for earnings per share of $0.16 for the first quarter of 2003 remains unchanged.
View HTML
Toggle Summary Integra LifeSciences Holdings Corporation to Sell $100 Million of Contingent Convertible Subordinated Notes
Integra LifeSciences Holdings Corporation to Sell $100 Million of Contingent Convertible Subordinated Notes Plainsboro, New Jersey - March 26, 2003 - Integra LifeSciences Holdings Corporation (Nasdaq: IART) announced that it has agreed to sell $100 million principal amount of its 2.5% contingent
View HTML
Toggle Summary Integra LifeSciences Announces Acquisition of JARIT Surgical Instruments; Raises Revenue and Earnings Guidance
Integra LifeSciences Announces Acquisition of JARIT Surgical Instruments; Raises Revenue and Earnings Guidance Plainsboro, NJ / March 18, 2003 / -- Integra LifeSciences Holdings Corporation (NASDAQ: IART - news) announced today that it has acquired JARIT® Surgical Instruments for
View HTML
Toggle Summary Integra LifeSciences Reports Record Earnings and Revenues for the Fourth Quarter and Full Year 2002
Integra LifeSciences Reports Record Earnings and Revenues for the Fourth Quarter and Full Year 2002 Click here for release.
View HTML